Masetti R, Bossu G, Muratore E, Leardini D, Gatti M, Di Sario R
Paediatr Drugs. 2024; 27(1):41-56.
PMID: 39503988
DOI: 10.1007/s40272-024-00663-5.
Shilpy N, Pushker N, Meel R, Agrawal S, Bajaj M, Sharma S
Med J Armed Forces India. 2024; 80(5):541-546.
PMID: 39309577
PMC: 11411301.
DOI: 10.1016/j.mjafi.2022.08.002.
Cheng L, You X, Wang X, Yu M, Jia C
Drug Des Devel Ther. 2024; 18:3617-3628.
PMID: 39156484
PMC: 11330242.
DOI: 10.2147/DDDT.S475706.
Li G, Li Q, Zhang C, Yu Q, Li Q, Zhou X
Front Genet. 2023; 14:1242711.
PMID: 37693307
PMC: 10484623.
DOI: 10.3389/fgene.2023.1242711.
Jiang Z, Wei Y, Huang W, Li B, Zhou S, Liao L
Front Pharmacol. 2022; 13:982981.
PMID: 36225581
PMC: 9549404.
DOI: 10.3389/fphar.2022.982981.
Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study.
Suetsugu K, Muraki S, Fukumoto J, Matsukane R, Mori Y, Hirota T
Drugs R D. 2021; 21(4):419-429.
PMID: 34655050
PMC: 8602551.
DOI: 10.1007/s40268-021-00365-0.
Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies.
Taghvaye-Masoumi H, Hadjibabaie M, Ghadimi M, Zarif-Yeganeh M, Vaezi M, Ghavamzadeh A
Iran J Pharm Res. 2021; 20(1):62-71.
PMID: 34400941
PMC: 8170753.
DOI: 10.22037/ijpr.2020.112330.13688.
Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 μg/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis.
Hanai Y, Hamada Y, Kimura T, Matsumoto K, Takahashi Y, Fujii S
J Fungi (Basel). 2021; 7(4).
PMID: 33923727
PMC: 8072959.
DOI: 10.3390/jof7040306.
Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?.
Chen T, Wang R, Lin Y, Chang K, Hung L, Teng C
Ther Adv Hematol. 2020; 11:2040620720965846.
PMID: 33194163
PMC: 7607783.
DOI: 10.1177/2040620720965846.
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.
Abdul-Aziz M, Alffenaar J, Bassetti M, Bracht H, Dimopoulos G, Marriott D
Intensive Care Med. 2020; 46(6):1127-1153.
PMID: 32383061
PMC: 7223855.
DOI: 10.1007/s00134-020-06050-1.
Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents.
Benitez L, Carver P
Drugs. 2019; 79(8):833-853.
PMID: 31093949
DOI: 10.1007/s40265-019-01127-8.
Antifungal Drugs Influence Neutrophil Effector Functions.
Ries F, Alflen A, Aranda Lopez P, Beckert H, Theobald M, Schild H
Antimicrob Agents Chemother. 2019; 63(6).
PMID: 30910895
PMC: 6535511.
DOI: 10.1128/AAC.02409-18.
The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.
Warrilow A, Parker J, Price C, Nes W, Garvey E, Hoekstra W
Antimicrob Agents Chemother. 2016; 60(8):4530-8.
PMID: 27161631
PMC: 4958158.
DOI: 10.1128/AAC.00349-16.
A retrospective analysis of patient-specific factors on voriconazole clearance.
Dote S, Sawai M, Nozaki A, Naruhashi K, Kobayashi Y, Nakanishi H
J Pharm Health Care Sci. 2016; 2:10.
PMID: 27096102
PMC: 4835838.
DOI: 10.1186/s40780-016-0044-9.
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
Jin H, Wang T, Falcione B, Olsen K, Chen K, Tang H
J Antimicrob Chemother. 2016; 71(7):1772-85.
PMID: 26968880
PMC: 4896404.
DOI: 10.1093/jac/dkw045.
Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.
Moriyama B, Kadri S, Henning S, Danner R, Walsh T, Penzak S
Curr Fungal Infect Rep. 2016; 9(2):74-87.
PMID: 26918067
PMC: 4764088.
DOI: 10.1007/s12281-015-0219-0.
Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.
Stine J, Lewis J
Expert Rev Gastroenterol Hepatol. 2015; 10(4):517-36.
PMID: 26633044
PMC: 5074808.
DOI: 10.1586/17474124.2016.1127756.
Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.
Shubitz L, Trinh H, Galgiani J, Lewis M, Fothergill A, Wiederhold N
Antimicrob Agents Chemother. 2015; 59(12):7249-54.
PMID: 26369964
PMC: 4649211.
DOI: 10.1128/AAC.00593-15.
Voriconazole and the liver.
Mihaila R
World J Hepatol. 2015; 7(14):1828-33.
PMID: 26207164
PMC: 4506940.
DOI: 10.4254/wjh.v7.i14.1828.
Pharmacogenomics of antimicrobial agents.
Aung A, Haas D, Hulgan T, Phillips E
Pharmacogenomics. 2014; 15(15):1903-30.
PMID: 25495412
PMC: 4296903.
DOI: 10.2217/pgs.14.147.